HomeAbout UsContact UsDisclaimer
Glossary of TermsFAQMetSyn CriteriaCarotid UltrasoundPublicationsDirections





NOTE:
This web site is currently still under construction. Any errors or omissions should be reported by clicking here.
*Adobe Acrobat Reader 5.0+ is required for files on this page, please visit here for a free version.


Title Author Year
Clinical Original
A polygenic basis for four classical Frederickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. View as PDF Hegele et al 2009
Alternate day dosing of rosuvastatin: Potential usefulness in statin-intolerant patients. View as PDF Joy, Hegele 2009
Predicting abdominal adipose tissue among women with familial partial lipodystrophy. View as PDF Joy et al 2009
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. View as PDF Edmondson et al 2009
A multiplex human syndrome implicates a key role for intestinal cell kinase in development of central nervous skeletal, and endocrine systems. View as PDF Lahiry et al 2009
Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. View as PDF Joy et al 2008
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. View as PDF Wang et al 2008
Polygenic determinants of severe hypertriglyceridemia. View as PDF Wang et al 2008
An unusual case of severe hypertriglyceridemia and splenomegaly. View as PDF Rahalkar et al 2008
Heterozygous CAV1 frameshift mutations (OMIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. View as PDF Cao et al 2008
Alstrom syndrome (OMIM 203800): A case report and literature review. View as PDF Joy et al 2007
Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. View as PDF Hegele, Al-Attar, Rutt 2007
Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). View as PDF Wang et al 2007
Genetic determinants of statin intolerance. View as PDF Oh et al 2007
Sequencing of the reannotated LMNB2 gene gene reveals novel mutations in patients with acquired partial lipodystrophy. View as PDF Hegele et al 2006
NPC1L1: Evolution From Pharmacological Target to Physiological Sterol Transporter. View as PDF Huff et al 2006
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. View as PDF Yuan et al 2006
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. View as PDF Tadiboyina et al 2005
NPC1L1 haplotype associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. View as PDF Hegele et al 2005
LMNA mutation position predicts organ system involvement in laminopathies. View as PDF Hegele 2005
Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. View as PDF Francis et al 2005
Phenotypic heterogeneity of sitosterolemia. View as PDF Wang et al 2004
 
Clinical Reviews
The end of the road for CETP inhibitors after torcetrapib? View as PDF Joy, Hegele 2009
Narrative review: Statin-related myopathy. View as PDF Joy, Hegele 2009
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Canadian Hypertension Education Program. View as PDF Khan et al 2009
Hypertriglyceridemia: phenomics and genomics. View as PDF Hegele, Pollex 2009
Emerging antidyslipidemic drugs. View as PDF Pollex, Joy, Hegele 2008
The failure of torcetrapib: What have we learned? View as PDF Joy, Hegele 2008
Microsomal triglyceride transfer protein inhibition-friend or foe? View as PDF Joy, Hegele 2008
Abetalipoproteinemia: Two case reports and literature review. View as PDF Zamel et al 2008
HIV-associated dyslipidaemia: pathogenesis and treatment. View as PDF Oh, Hegele 2007
Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum. View as PDF Rahalkar, Hegele 2008
Inherited lipodystrophies and the metabolic syndrome. View as PDF Monajemi et al 2007
Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. View as PDF Khan et al 2007
Lipodystrophies: windows on adipose biology and metabolism. View as PDF Hegele, Joy, Al-Attar, Rutt 2007
Phenomics and lamins: From disease to therapy. View as PDF Hegele, Oshima 2007
Hypertriglyceridemia: its etiology, effects and treatment. View as PDF Yuan, Al-Shali, Hegele 2007
Genetic forms of the cardiometabolic syndrome: What can they tell the clinician? View as PDF Yuan, Hegele 2007
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. View as PDF Yuan, Wang, Hegele 2006
ABC transporters and sterol absorption. View as PDF Hegele, Robinson 2005
Treatment of partial lipodystrophy; can the zebra teach us about the horse? View as PDF Hegele 2004
Hutchinson-Gilford progeria syndrome. View as PDF Pollex, Hegele 2004
A glimpse at HDL-based therapy for atherosclerosis. Hegele 2004

OTHER PUBLICATIONS

Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive Protein. View As PDF Ridker et al 2008
Optimal Medical Therapy with or without PCI for Stable Coronary Disease. View As PDF Boden et al 2007
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. View as PDF Deedwania et al 2006
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. View As PDF Lonn et al 2006
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. View as PDF Lonn et al 2006
Dyslipidemia in Adults With Diabetes. View as PDF N/A 2006
Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. View As PDF McPherson et al 2006
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. View as PDF Cholesterol Treatment Trialists' 2005
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. View as PDF Pedersen et al 2005
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. View as PDF LaRosa et al 2005
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. View As PDF Baigent et al 2005
High-dose Atorvastatin vs usual-dose Simvastatin for secondary prevention after myocardial infarction. View As PDF Pedersen et al 2005
Intensive lipid lowering with Atorvastatin in patients with stable coronary disease. View As PDF LaRosa et al 2005
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. View as PDF Cannon et al 2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. View as PDF Colhoun et al 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. View As PDF Cannon et al 2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. View As PDF Colhoun et al 2004
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. View as PDF Sever et al 2003
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. View As PDF Sever et al 2003
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL cholesterol. View As PDF Rubins et al 1999
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. View as PDF Hanna et al 1997

 
Home | Services | Contact Us | Disclaimer | Privacy Policy
@2007 BCGL-LGC
Created by Ayaz Mosa Maintained by Ericka Simon